Hunter Capital (HUNTER) Q2 2025 earnings summary

Executive summary

• Achieved a significant increase in profit after financial items, reaching 30.04 MSEK for the quarter compared to 3.36 MSEK year-over-year.

• Completed a major asset sale to Vultus AB (now C100 AB), receiving 25 MSEK in shares.

• Acquired intellectual property from Redwood Pharma AB's bankruptcy estate, aligning with the opportunistic investment strategy.

• Participated as a lead investor in SynAct Pharma's directed share issue, reinforcing commitment to life science investments.

Financial highlights

• Net sales for the quarter were 0 SEK (0 SEK last year); for the six months, 18 TSEK (325 TSEK last year).

• EBITDA for the quarter was -702 TSEK (-394 TSEK last year); for six months, -1.57 MSEK (-590 TSEK last year).

• Result after financial items for the quarter was 30.04 MSEK (3.36 MSEK last year); for six months, 31.19 MSEK (3.16 MSEK last year).

• Earnings per share for the quarter was 6.61 SEK (0.95 SEK last year); for six months, 6.87 SEK (0.89 SEK last year).

• Cash and cash equivalents at period end were 3.13 MSEK (1.99 MSEK last year).

Outlook and guidance

• Management continues to pursue high business tempo and seeks new value-creating opportunities in a challenging market.

• A reverse profit warning was issued due to a substantial increase in profit after financial items.